anti-CD20 bispecific antibody DR-0201

A bispecific monoclonal antibody that targets the human tumor-associated antigen (TAA) CD20, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD20 bispecific antibody DR-0201 targets and binds to CD20 on B-cell surface. This results in CD20-mediated signaling blockade and may induce phagocytosis of CD20-overexpressing cells by tissue-resident and trafficking myeloid cells, such as macrophages. This results in a depletion of pathogenic B cells. CD20 is overexpressed by certain cancer cell types and in various autoimmune diseases.